These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 27903791)
1. Rapid and partial remission of primary lesion but complicated by secondary fibrosis after treatment with nivolumab in a lung squamous carcinoma. Ding L; Zhu Y; Chen C Ther Adv Respir Dis; 2017 Feb; 11(2):129-132. PubMed ID: 27903791 [No Abstract] [Full Text] [Related]
2. Nivolumab-induced Pancreatitis: An Immune-related Adverse Event. Saito H; Ono K Radiology; 2019 Dec; 293(3):521. PubMed ID: 31617817 [No Abstract] [Full Text] [Related]
3. Three cases of immune cholangitis related to anti-programmed cell death and programmed cell death ligand agents for the treatment of non-small cell lung cancer. Fouchard M; Jantzem H; Quere G; Descourt R; Robinet G; Poureau PG Eur J Cancer; 2019 Jul; 115():107-110. PubMed ID: 31132740 [No Abstract] [Full Text] [Related]
4. Drug-induced myocarditis after nivolumab treatment in a patient with PDL1- negative squamous cell carcinoma of the lung. Semper H; Muehlberg F; Schulz-Menger J; Allewelt M; Grohé C Lung Cancer; 2016 Sep; 99():117-9. PubMed ID: 27565924 [TBL] [Abstract][Full Text] [Related]
5. NICE guidance on necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer. Umeweni N; Knight H; McVeigh G Lancet Oncol; 2016 Nov; 17(11):1483-1484. PubMed ID: 27692477 [No Abstract] [Full Text] [Related]
6. Coincidence of immunotherapy-associated hemophagocytic syndrome and rapid tumor regression. Takeshita M; Anai S; Mishima S; Inoue K Ann Oncol; 2017 Jan; 28(1):186-189. PubMed ID: 28043982 [No Abstract] [Full Text] [Related]
8. Durvalumab-induced Organizing Pneumonia with a Diffuse Micronodular Pattern in a Patient with Lung Cancer. Yamasaki M; Taniwaki M; Kawamoto K; Matsumoto N; Hashimoto K; Nabeshima S; Ohashi N; Hattori N Am J Respir Crit Care Med; 2020 Apr; 201(8):e52-e53. PubMed ID: 31710509 [No Abstract] [Full Text] [Related]
9. Long-lasting shrinkage in tumor mass after discontinuation of nivolumab treatment. Kimura H; Sone T; Murata A; Koba H; Tambo Y; Hara J; Abo M; Kasahara K Lung Cancer; 2017 Jun; 108():7-8. PubMed ID: 28625651 [TBL] [Abstract][Full Text] [Related]
10. Development of psoriatic arthritis during nivolumab therapy for metastatic non-small cell lung cancer, clinical outcome analysis and review of the literature. Ruiz-Bañobre J; Pérez-Pampín E; García-González J; Gómez-Caamaño A; Barón-Duarte FJ; López-López R; Vázquez-Rivera F Lung Cancer; 2017 Jun; 108():217-221. PubMed ID: 28625638 [TBL] [Abstract][Full Text] [Related]
11. Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases. Dudnik E; Yust-Katz S; Nechushtan H; Goldstein DA; Zer A; Flex D; Siegal T; Peled N Lung Cancer; 2016 Aug; 98():114-117. PubMed ID: 27393516 [TBL] [Abstract][Full Text] [Related]
12. [A case of meningoencephalitis associated with pembrolizumab treated for squamous cell lung cancer]. Yonenobu Y; Ishijima M; Toyooka K; Fujimura H Rinsho Shinkeigaku; 2019 Feb; 59(2):105-108. PubMed ID: 30700688 [TBL] [Abstract][Full Text] [Related]
13. [Dermatomyositis with squamous cell carcinoma of the lungs secondary to nivolumab treatment: a case report]. Miyashita K; Kajikawa H; Utsunomiya T; Hosaka M; Naito Y; Tomimoto H Rinsho Shinkeigaku; 2020 Nov; 60(11):768-772. PubMed ID: 33115992 [TBL] [Abstract][Full Text] [Related]
14. Severe myocarditis with slight lymphocytic infiltration after nivolumab treatment. Edahiro R; Shiroyama T; Hijiki S; Nojima S; Shirai Y; Koyama S; Kumanogoh A Lung Cancer; 2020 Feb; 140():116-117. PubMed ID: 31848027 [No Abstract] [Full Text] [Related]
15. Development of mild drug-induced sclerosing cholangitis after discontinuation of nivolumab. Noda-Narita S; Mizuno S; Noguchi S; Watanabe K; Nakai Y; Koike K; Kage H; Nagase T Eur J Cancer; 2019 Jan; 107():93-96. PubMed ID: 30554074 [No Abstract] [Full Text] [Related]
16. Nivolumab-induced organizing pneumonitis in a patient with lung sarcomatoid carcinoma. Gounant V; Brosseau S; Naltet C; Opsomer MA; Antoine M; Danel C; Khalil A; Cadranel J; Zalcman G Lung Cancer; 2016 Sep; 99():162-5. PubMed ID: 27565934 [TBL] [Abstract][Full Text] [Related]
17. Organizing Pneumonia after Nivolumab Treatment in a Patient with Pathologically Proven Idiopathic Pulmonary Fibrosis. Kashiwada T; Minegishi Y; Saito Y; Kato T; Atsumi K; Seike M; Kubota K; Terasaki Y; Gemma A J Nippon Med Sch; 2019; 86(1):43-47. PubMed ID: 30918156 [TBL] [Abstract][Full Text] [Related]
18. Stevens-Johnson syndrome associated with radiation recall dermatitis in a patient treated with nivolumab. Rouyer L; Bursztejn AC; Charbit L; Schmutz JL; Moawad S Eur J Dermatol; 2018 Jun; 28(3):380-381. PubMed ID: 29952288 [No Abstract] [Full Text] [Related]
19. Spontaneous hematoma of the thigh associated with antiproteinase-3 antibody in a patient with metastatic squamous cell carcinoma treated with nivolumab. Keung YK; Hu EH J Oncol Pharm Pract; 2019 Jul; 25(5):1261-1264. PubMed ID: 29984627 [TBL] [Abstract][Full Text] [Related]
20. Relapse of morphea during Nivolumab therapy for lung adenocarcinoma. Alegre-Sánchez A; Fonda-Pascual P; Saceda-Corralo D; de Las Heras-Alonso E Actas Dermosifiliogr; 2017; 108(1):69-70. PubMed ID: 27663405 [No Abstract] [Full Text] [Related] [Next] [New Search]